Abpro further commits to Asia in $1.1B bispecific deal March 3, 2020 By Lee Landenberger No Comments Abpro Therapeutics Inc. has granted an exclusive license to Abpro Bio Co. Ltd., the former Ugint Co. Ltd., to develop and commercialize two bispecific antibodies in Asian markets, including greater China, Japan and South Korea.Read More